Tomoko Matsui
Kobe, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Biological Differences between EGFR ex19del and ex21L858R-Preclinical Models Using an Engineered Pair of Isogenic NSCLC Cell Lines with CRISPR Engineering
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: October 06, 2025
Mutation-Specific Response to Ramucirumab in EGFR-Mutated Metastatic NSCLC: Insights From Circulating Cell-Free DNA Profiling (Liquid Biopsy Japan Addendum of RELAY Phase 3 Randomized Study).
Journal: JTO clinical and research reports
Published: September 29, 2025
RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic EGFR-mutated NSCLC.
Journal: Future oncology (London, England)
Published: September 25, 2025
RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC.
Journal: JTO clinical and research reports
Published: May 20, 2025
Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset.
Journal: JTO clinical and research reports
Published: December 19, 2024
RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants.
Journal: JTO clinical and research reports
Published: September 08, 2023
Patients' Preferences for Attributes of Molecular Targeting Therapies for Advanced Non-Small Cell Lung Cancer with EGFR Mutations in Japan-A Discrete-Choice Experiment.
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: December 20, 2022
Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study).
Journal: Translational lung cancer research
Published: October 11, 2022
Differences between EGFR Exon 19 Deletion and Exon 21 L858R Point Mutation, Frequently Detected EGFR Mutations in Patients with Non-Small Cell Lung Cancer, from a Molecular Biology Viewpoint
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: December 16, 2021
RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC.
Journal: JTO clinical and research reports
Published: December 16, 2021
Exon 19 Deletion and Exon 21 L858R Point Mutation in EGFR Mutation‒Positive Non‒Small Cell Lung Cancer
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: May 19, 2021
Single-molecule lactonization of octadecylrhodamine B at a liquid-liquid interface.
Journal: Langmuir : the ACS journal of surfaces and colloids
Published: October 26, 2012
Showing 1-12 of 12
Last Updated: 09/26/2026